The EDGE

Stem cell divisions and cancer

P J Quesenberry and L R Goldberg

Leukemia 2015 29: 1959; advance online publication, July 31, 2015; 10.1038/leu.2015.166

Reviews

OCT1 and imatinib transport in CML: is it clinically relevant?

D B Watkins, T P Hughes and D L White

Leukemia 2015 29: 1960-1969; advance online publication, July 9, 2015; 10.1038/leu.2015.170

Mouse models for core binding factor leukemia

D W L Chin, N Watanabe-Okochi, C Q Wang, V Tergaonkar and M Osato

Leukemia 2015 29: 1970-1980; advance online publication, July 13, 2015; 10.1038/leu.2015.181

Original Articles

ACUTE MYELOID LEUKEMIA

Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia

J Khalife, H S Radomska, R Santhanam, X Huang, P Neviani, J Saultz, H Wang, Y-Z Wu, H Alachkar, M Anghelina, A Dorrance, J Curfman, C D Bloomfield, B C Medeiros, D Perrotti, L J Lee, R J Lee, M A Caligiuri, F Pichiorri, C M Croce, R Garzon, M L Guzman, J H Mendler and G Marcucci

Leukemia 2015 29: 1981-1992; advance online publication, May 14, 2015; 10.1038/leu.2015.106

CHRONIC MYELOGENOUS LEUKEMIA

The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells

L Mourgues, V Imbert, M Nebout, P Colosetti, Z Neffati, P Lagadec, E Verhoeyen, C Peng, E Duprez, L Legros, N Rochet, V Maguer-Satta, F-E Nicolini, D Mary and J-F Peyron

Leukemia 2015 29: 1993-2002; advance online publication, April 30, 2015; 10.1038/leu.2015.112

CHRONIC LYMPHOCYTIC LEUKEMIA

The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL

E Vasyutina, J M Boucas, J Bloehdorn, C Aszyk, G Crispatzu, M Stiefelhagen, A Breuer, P Mayer, C Lengerke, H Döhner, D Beutner, A Rosenwald, S Stilgenbauer, M Hallek, A Benner and M Herling

Leukemia 2015 29: 2003-2014; advance online publication, May 4, 2015; 10.1038/leu.2015.114

p53-dependent non-coding RNA networks in chronic lymphocytic leukemia

C J Blume, A Hotz-Wagenblatt, J Hüllein, L Sellner, A Jethwa, T Stolz, M Slabicki, K Lee, A Sharathchandra, A Benner, S Dietrich, C C Oakes, P Dreger, D te Raa, A P Kater, A Jauch, O Merkel, M Oren, T Hielscher and T Zenz

Leukemia 2015 29: 2015-2023; advance online publication, May 14, 2015; 10.1038/leu.2015.119

LYMPHOMA

Versican upregulation in Sézary cells alters growth, motility and resistance to chemotherapy

K Fujii, M B Karpova, K Asagoe, O Georgiev, R Dummer and M Urosevic-Maiwald

Leukemia 2015 29: 2024-2032; advance online publication, April 27, 2015; 10.1038/leu.2015.103

MULTIPLE MYELOMA, GAMMOPATHIES

Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy

M Alhaj Moustafa, S V Rajkumar, A Dispenzieri, M A Gertz, M Q Lacy, F K Buadi, Y L Hwa, D Dingli, P Kapoor, S R Hayman, J A Lust, R A Kyle and S K Kumar

Leukemia 2015 29: 2033-2038; advance online publication, May 12, 2015; 10.1038/leu.2015.118

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

I S Nijhof, R W J Groen, H M Lokhorst, B van Kessel, A C Bloem, J van Velzen, R de Jong-Korlaar, H Yuan, W A Noort, S K Klein, A C M Martens, P Doshi, K Sasser, T Mutis and N W C J van de Donk

Leukemia 2015 29: 2039-2049; advance online publication, May 15, 2015; 10.1038/leu.2015.123

CHRONIC MYLEPROLIFERATIVE NEOPLASMS

Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice

D Yan, F Jobe, R E Hutchison and G Mohi

Leukemia 2015 29: 2050-2061; advance online publication, May 18, 2015; 10.1038/leu.2015.116

STEM CELL TRANSPLANTATION

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

R Zeiser, A Burchert, C Lengerke, M Verbeek, K Maas-Bauer, S K Metzelder, S Spoerl, M Ditschkowski, M Ecsedi, K Sockel, F Ayuk, S Ajib, F S de Fontbrune, I-K Na, L Penter, U Holtick, D Wolf, E Schuler, E Meyer, P Apostolova, H Bertz, R Marks, M Lübbert, R Wäsch, C Scheid, F Stölzel, R Ordemann, G Bug, G Kobbe, R Negrin, M Brune, A Spyridonidis, A Schmitt-Gräff, W van der Velden, G Huls, S Mielke, G U Grigoleit, J Kuball, R Flynn, G Ihorst, J Du, B R Blazar, R Arnold, N Kröger, J Passweg, J Halter, G Socié, D Beelen, C Peschel, A Neubauer, J Finke, J Duyster and N von Bubnoff

Leukemia 2015 29: 2062-2068; advance online publication, July 31, 2015; 10.1038/leu.2015.212

CYTOGENETICS AND MOLECULAR GENETICS

Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus OPEN

A Chase, W Leung, W Tapper, A V Jones, L Knoops, C Rasi, L A Forsberg, P Guglielmelli, K Zoi, V Hall, L Chiecchio, L Eder-Azanza, C Bryant, L Lannfelt, L Docherty, H E White, J Score, D J G Mackay, A M Vannucchi, J P Dumanski and N C P Cross

Leukemia 2015 29: 2069-2074; advance online publication, May 20, 2015; 10.1038/leu.2015.130

ANIMAL MODELS

Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML

C E Forristal, A L Brown, F M Helwani, I G Winkler, B Nowlan, V Barbier, R J Powell, G A Engler, S M Diakiw, A C W Zannettino, S Martin, D Pattabiraman, R J D'Andrea, I D Lewis and J P Levesque

Leukemia 2015 29: 2075-2085; advance online publication, April 29, 2015; 10.1038/leu.2015.102

Epigenetic therapy restores normal hematopoiesis in a zebrafish model of NUP98–HOXA9-induced myeloid disease

A P Deveau, A M Forrester, A J Coombs, G S Wagner, C Grabher, I C Chute, D Léger, M Mingay, G Alexe, V Rajan, R Liwski, M Hirst, K Steigmaier, S M Lewis, A T Look and J N Berman

Leukemia 2015 29: 2086-2097; advance online publication, May 28, 2015; 10.1038/leu.2015.126

Letters to the Editor

Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma

E Brissot, A Clavert, N Blin, V Roland, T Guillaume, V Dubruille, B Mahe, T Gastinne, S Le Gouill, B Gaugler, P Moreau and M Mohty

Leukemia 2015 29: 2098-2100; advance online publication, March 9, 2015; 10.1038/leu.2015.64

A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone OPEN

C N Hahn, D M Ross, J Feng, A Beligaswatte, D K Hiwase, W T Parker, M Ho, M Zawitkowski, K L Ambler, G D Cheetham, Y K Lee, M Babic, C M Butcher, G A Engler, A L Brown, R J D'Andrea, I D Lewis, A W Schreiber, L B To and H S Scott

Leukemia 2015 29: 2101-2104; advance online publication, March 9, 2015; 10.1038/leu.2015.67

Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia

R B Walter, M Othus, E M Paietta, J Racevskis, H F Fernandez, J-W Lee, Z Sun, M S Tallman, J Patel, M Gönen, O Abdel-Wahab, R L Levine and E H Estey

Leukemia 2015 29: 2104-2107; advance online publication, March 16, 2015; 10.1038/leu.2015.76

Refinement of IKZF1 status in pediatric Philadelphia-positive acute lymphoblastic leukemia

T Lana, P de Lorenzo, S Bresolin, I Bronzini, M L den Boer, H Cavé, E Froňková, M Stanulla, M Zaliova, C J Harrison, H de Groot, M G Valsecchi, A Biondi, G Basso, G Cazzaniga and G te Kronnie

Leukemia 2015 29: 2107-2110; advance online publication, March 17, 2015; 10.1038/leu.2015.78

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

B Paiva, A Azpilikueta, N Puig, E M Ocio, R Sharma, B O Oyajobi, S Labiano, L San-Segundo, A Rodriguez, I Aires-Mejia, I Rodriguez, F Escalante, A G de Coca, A Barez, J F San Miguel and I Melero

Leukemia 2015 29: 2110-2113; advance online publication, March 17, 2015; 10.1038/leu.2015.79

Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma

Z Li, F Stölzel, K Onel, M Sukhanova, M K Mirza, K L Yap, O Borinets, R A Larson, W Stock, M M Sasaki, L Joseph and G Raca

Leukemia 2015 29: 2113-2116; advance online publication, March 19, 2015; 10.1038/leu.2015.81

Correspondence

Should we also evaluate SET together with CIP2A for the treatment with second-generation tyrosine kinase inhibitors in chronic myeloid leukemia?

I Cristóbal, R Manso, P González-Alonso, F Rojo and J García-Foncillas

Leukemia 2015 29: 2117; advance online publication, August 18, 2015; 10.1038/leu.2015.201